References
- EMCDDA – Perspectives on drugs. Synthetic cannabinoids in Europe [Internet]; [cited 2016 March 10]. Available from: http://www.emcdda.europa.eu/attachements.cfm/att_212361_EN_EMCDDA_POD_2013_Synthetic%20cannabinoids.pdf.
- UNODOC, Global SMART Update Volume 13, March 2015 [Internet]; [cited 2016 March 10]. Available from: https://www.unodc.org/documents/scientific/Synthetic_Cannabinoids.pdf.
- Adamowicz P, Gieroń J, Gil D, et al. The prevalence of new psychoactive substances in biological material – a three-year review of casework in Poland. Drug Test Anal. 2016;8:64–71.
- Buchler IP, Hayes MJ, Hedge SG, et al. Indazole derivatives. PCT/IB2009/000432 1-283. Patent 2009.
- [Internet]; [cited 2016 March 10]. Available from: http://www.tvp.info/20805889/to-nie-sa-zadne-dopalacze-to-sa-narkotyki-o-sile-dzialania-800-razy-wiekszej-niz-marihuana.
- Adamowicz P, Tokarczyk B. Simple and rapid screening procedure for 143 new psychoactive substances by liquid chromatography-tandem mass spectrometry. Drug Test Anal. 2015. [Epub ahead of print]. doi:10.1002/dta.1815.
- Note on outbreak of intoxications suspected to be caused by legal high product name “Mocarz” in Poland (2016) [Internet]. [cited 2016 March 10]. Available from: https://legal-high-inhaltsstoffe.de/sites/default/files/uploads/information_mocarz.pdf.
- EMCDDA-Europol 2014 Annual Report on the implementation of Council Decision 2005/387/JHA [Internet]; [cited 2016 March 10]. Available from: http://www.emcdda.europa.eu/system/files/publications/1018/TDAN15001ENN.pdf.
- [Internet]; (cited 2016 March 10). Available from: https://legal-high-inhaltsstoffe.de/sites/default/files/uploads/am-2201.pdf.
- Gurney SM, Scott KS, Kacinko SL, et al. Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Sci Rev. 2014;26:53–78.
- Papanti D, Orsolini L, Francesconi G, et al. “Noids” in a nutshell: everything you (don’t) want to know about synthetic cannabimimetics. Adv Dual Diagn. 2014;7:137–148.
- Early warning system reports. Accessible via EDND database of the EMCDDA [Internet]; [cited 2016 March 10]. Available from: http://ednd.emcdda.europa.eu/.
- Department of Justice, Drug Enforcement Administration. Schedules of controlled substances: Temporary placement of the synthetic cannabinoid MAB-CHMINACA into Schedule I. Federal Register, Vol. 80, No. 179, 55565–55568.
- [Internet]; (cited 2016 March 10). Available from: http://www.nytimes.com/2015/04/25/health/surge-in-hospital-visits-linked-to-a-drug-called-spice-alarms-health-officials.html?_r=1.
- [Internet]; (cited 2016 March 10). Available from: http://www.huffingtonpost.com/2015/05/08/synthetic-marijuana-hospitalizations_n_7241772.html.
- [Internet]; (cited 2016 March 10). Available from: http://new.dhh.louisiana.gov/index.cfm/newsroom/detail/3161.
- Trecki J, Gerona RR, Schwartz MD. Synthetic cannabinoid-related illnesses and deaths. N Engl J Med. 2015;373:103–107.
- Hasegawa K, Wurita A, Minakata K, et al. Postmortem distribution of MAB-CHMINACA in body fluids and solid tissues of a human cadaver. Forensic Toxicol. 2015;33:380–387.